Cantor Fitzgerald Initiates Pernix Therapeutics At Buy

Analysts at Cantor Fitzgerald initiated coverage on Pernix Therapeutics Holdings, Inc. PTX with a Buy rating. The target price for Pernix Therapeutics is set to $11. Pernix Therapeutics shares have gained 172.33% over the past 52 weeks, while the S&P 500 index has surged 12.47% in the same period. Pernix Therapeutics' shares jumped 1.59% to $8.30 in after-hours trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: InitiationAnalyst RatingsCantor Fitzgerald
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!